|Assessment Status||Assessment process complete.|
|Drug||Human alpha1-proteinase inhibitor (A1PI)|
|Indication||For long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability).|
|Rapid review commissioned||05/05/2017|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.